The Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Hypoxia is an important feature of most solid tumors, conferring resistance to radiation and many forms of chemotherapy. However, it is possible to exploit the presence of tumor hypoxia with hypoxia-activated prodrugs (HAPs), agents that in low oxygen conditions undergo bioreduction to yield cytotoxic metabolites. Although many such agents have been developed, we will focus here on TH-302. TH-302 has been extensively studied, and we discuss its mechanism of action, as well as its efficacy in preclinical and clinical studies, with the aim of identifying future research directions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jayaprakash, P., Ai, M., Liu, A., Budhani, P., Bartkowiak, T., Sheng, J., Ager, C., Nicholas, C., Jaiswal, A. R., Sun, Y., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96268 · Cited by 399 · cited 1×
“To overcome this, they combined TH-302 with a maximal checkpoint blockade directed against both CTLA-4 and PD-1, dramatically enhancing the effect of the immunotherapy treatment (Jayaprakash et al., 2018).”
Borad, M. J., Reddy, S. G., Bahary, N., Uronis, H. E., Sigal, D., Cohn, A. L., Schelman, W. R., Stephenson, J., Chiorean, E. G., Rosen, P. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7504 · Cited by 197
Chawla, S. P., Cranmer, L. D., Van Tine, B. A., Reed, D. R., Okuno, S. H., Butrynski, J. E., Adkins, D. R., Hendifar, A. E., Kroll, S., & Ganjoo, K. N. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.3660 · Cited by 155
Liu, Q., Sun, J. D., Wang, J., Ahluwalia, D., Baker, A. F., Cranmer, L. D., Ferraro, D., Wang, Y., Duan, J.-X., Ammons, W. S., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1852-8 · Cited by 113 · cited 1×
“Combination of TH-302 With Conventional Chemotherapy TH-302 has been shown to enhance the anti-tumor effect of many conventional chemotherapy drugs, such as docetaxel, cisplatin, pemetrexed, irinotecan, doxorubicin, gemcitabine, temozolomide, and topotecan (Liu et al., 2012; Saggar and Tannock, 2014; Liapis et al., 20…”
BackgroundVoissiere, A., Jouberton, E., Maubert, E., Degoul, F., Peyrode, C., Chezal, J.-M., & Miot-Noirault, É. (2017) · PLOS ONE · doi:10.1371/journal.pone.0181340 · Cited by 49
Haynes, J., McKee, T. D., Haller, A., Wang, Y., Leung, C., Gendoo, D. M. A., Lima-Fernandes, E., Kreso, A., Wolman, R., Szentgyorgyi, E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1715 · Cited by 22 · cited 1×
“investigated and proposed that conventional treatments such as fluorouracil with or without radiotherapy, would enhance tumor hypoxia and thus expand the C-IC population, which could be counteracted by TH-302 treatment (Haynes et al., 2018).”
Background
Cited by
Hypoxia signaling in human health and diseases: implications and prospects for therapeutics
Luo, Z., Tian, M., Yang, G., Tan, Q., Chen, Y., Li, G., Zhang, Q., Li, Y., Wan, P., & Wu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01080-1 · Cited by 499
Self-citationHypoxia and the Tumor Microenvironment
Li, Y., Zhao, L., & Li, X.-F. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/15330338211036304 · Cited by 394
Self-citationDavis, L., Recktenwald, M., Hutt, E., Fuller, S., Briggs, M., Goel, A., & Daringer, N. (2022) · Cancers · doi:10.3390/cancers14051259 · Cited by 83
Benoit, A., Vogin, G., Duhem, C., Berchem, G., & Janji, B. (2023) · Cells · doi:10.3390/cells12131787 · Cited by 39
“The activation of TH302 occurs under hypoxia based on the reduction in free radical anions, leading to the release of bromo-iso-phosphoramide mustard (Br-IPM) or its stable downstream product, isophosphoramide mustard (IPM) [142].”
Background
Metadata
- Authors
- Li, Y., Zhao, L., & Li, X.-F.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2021-04-19
- Volume
- 12
- Pages
- 636892-636892
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W3152633828
- Cited by
- 70
- References
- 6
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.